Scale-up and tech transfer in the pharmaceutical industry are intricate processes that require cross-functional collaboration and transparent communication to mitigate risks and avoid interruption to a project's progress. In a CDMO partnership, the expertise of the CDMO should mirror that of the client's organization to ensure a clear, mutual understanding of all development, manufacturing, quality and regulatory considerations.
UPM has a strong legacy of successfully scaling up to commercialization, maintaining product quality and homogeneity from lab-scale to commercial quantities. Each stage is planned with the next one in mind, so moving from clinical to commercial manufacturing builds on the process you've already proven instead of starting over.
We understand you are the greatest source of knowledge when it comes to your project’s history as well as your long-term goals. Our multidisciplinary tech transfer team—comprising experts in R&D, manufacturing, engineering, quality and regulatory affairs—will work with you and your teams to understand your pharma technology transfer project from every aspect, with full transparency into all future activities and open access to all project stakeholders. Every transfer follows the tech transfer best practices and checklist we've refined across more than 80 products brought to market. Let UPM’s track record of success and creative problem-solving get you to where you want to go.
Send us the molecule, the dosage form and the constraints — potency, schedule, process, or anything that has made other CDMOs hesitate. We'll tell you whether we can work with it.
UPM Pharmaceuticals Welcomes Back Pat Hatem as Vice President of Manufacturing and Packaging
VIEW FULL CONTENT
